# Caroline Lohrisch

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/caroline-lohrisch/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,533 |
| Field | Breast Cancer Treatment Studies |
| h-index | 29 |
| i10-index | 47 |
| Last Known Institution | BC Cancer Agency |
| OpenAlex ID | https://openalex.org/A5051673242 |
| ORCID iD | 0000-0003-0478-5987 |
| Works | 171 |

## Researcher papers

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer](https://scholariq.org/papers/impact-on-survival-of-time-from-definitive-surgery-to-initiation-of-adjuvant/)
- [Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer](https://scholariq.org/papers/mature-results-of-a-randomized-phase-ii-multicenter-study-of-exemestane-versus/)
- [Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial](https://scholariq.org/papers/doxorubicin-and-paclitaxel-versus-doxorubicin-and-cyclophosphamide-as-first-line/)
- [Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer](https://scholariq.org/papers/homologous-recombination-deficiency-and-platinum-based-therapy-outcomes-in/)
- [Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed](https://scholariq.org/papers/survival-with-metastatic-breast-cancer-based-on-initial-presentation-de-novo/)
- [Small cell carcinoma of the bladder](https://scholariq.org/papers/small-cell-carcinoma-of-the-bladder/)
- [The Predictive Value of HER2 in Breast Cancer](https://scholariq.org/papers/the-predictive-value-of-her2-in-breast-cancer/)
- [Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?](https://scholariq.org/papers/second-and-subsequent-lines-of-chemotherapy-for-metastatic-breast-cancer-what/)
- [Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients](https://scholariq.org/papers/breast-conserving-therapy-is-associated-with-improved-survival-without-an/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)

## Researcher university

- [BC Cancer Agency](https://scholariq.org/institutions/bc-cancer-agency/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.